Related Experiment Video
Updated: Jan 16, 2026
Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model
Published on: June 4, 2017
Targeting glioblastoma using oncolytic viruses delivered by human pluripotent stem cell-derived neural progenitor
Jianfei Chao1, Qi Cui1, Peng Ye1
1Department of Neurodegenerative Diseases, Beckman Research Institute of City of Hope, 1500 E. Duarte Road, Duarte, CA 91010, USA.
Abstract:
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor that has no cure. Oncolytic virotherapy is emerging as an effective approach to target cancer cells. Here, we show that the CF17 oncolytic virus, either delivered directly or by human pluripotent stem cell (hPSC)-derived neural progenitor cell (NPC) carrier, exerts strong growth inhibitory effect on GBM stem cells (GSCs) in vitro. More tumor cells were targeted by oncolytic virus in NPC-carried CF17-GFP-treated brains than that in CF17-GFP alone-treated brains, and more reduction in the tumor cell number was detected in CF17-GFP-NPC-treated mouse brains, compared to CF17-GFP alone-treated brains 7 days after treatment. Moreover, we show that CF17, either delivered directly or carried by NPCs, can suppress GSC-derived GBM tumor progression and prolong the survival of tumor-bearing mice substantially in a GBM mouse model. Therefore, our study identifies the CF17 oncolytic virus as a promising therapeutic candidate for GBM in more than one way of delivery.
Insights
This study shows that the CF17 oncolytic virus effectively inhibits glioblastoma stem cells. Delivering the virus via neural progenitor cells enhances its tumor-targeting ability and improves survival in a mouse model.
Area of Science:
- Oncology
- Virology
- Neuroscience
Background:
- Glioblastoma multiforme (GBM) is an aggressive brain tumor with no cure.
- Oncolytic virotherapy offers a potential strategy for targeting cancer cells.
Purpose of the Study:
- To evaluate the efficacy of the CF17 oncolytic virus against glioblastoma stem cells (GSCs).
- To assess the therapeutic potential of CF17 delivered directly or via neural progenitor cell (NPC) carriers.
Main Methods:
- In vitro studies on GSCs treated with CF17 virus.
- In vivo studies using a GBM mouse model with direct CF17 delivery or NPC-carried CF17.
- Assessment of tumor cell targeting, reduction, tumor progression, and survival rates.
Main Results:
- CF17 virus demonstrated significant growth inhibition of GSCs in vitro.
- NPC-carried CF17 showed enhanced tumor cell targeting and reduction in vivo compared to direct delivery.
- Both delivery methods suppressed GBM tumor progression and prolonged survival in mice.
Conclusions:
- CF17 oncolytic virus is a promising therapeutic candidate for GBM.
- NPCs can serve as effective carriers for oncolytic viruses, enhancing their delivery and efficacy.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
09:18Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
Published on: July 16, 2018